NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/04/2024
Voltar para busca
Dado oficial do USPTO
PSARLINK
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
28/04/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
15/07/2020
Data de registro
26/10/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/10/2021
Última transação
14/03/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
FR
Examinador
PEISECKI, MARK
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
M. B. (pessoa física)
Representantes
John R. Rudolph Eli Lilly and Company
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemicalbiological and biotechnological preparations for use in industry and science ; chemical substances for the manufacture of pharmaceutical products for non-medical purposesfor use in manufacturing of antibody conjugates ; chemical substances for tethering moleculesin particular chemical substances for tethering molecules for cancer therapyfor research in active substances and medicines other than for medical or veterinary purposes; chemical substances for the formation of antibody conjugates for use in laboratoriesother than for medical or veterinary purposes ; chemical reagents for scientific purposes other than for medical or veterinary purposes; reagents for scientific or medical research; chemicalbiochemical and biological reagents for scientific or medical research use; chemicals for bioconjugationreversible cysteine protectionsurface modificationthe production of prodrugs for use in laboratoriesother than for medical or veterinary purposes; antibodies and antibody conjugates for scientific purposesother than for medical or veterinary purposes; antibodies for scientific or medical research; molecules and biomoleculesreagentsantibody fragmentsantibodiesall intended for fundamental research and developmentmedical research and scientific diagnosis; Diagnostic products for scientific or research use related to conjugated antibodiesdiagnostic preparations for scientific use
Classe 5
Pharmaceutical preparations for the treatment of cancer ; pharmaceutical products for the prevention or treatment of human diseasesthe treatment of cancer; chemicalbiological and biochemical products for medical and pharmaceutical useantibody-drug conjugates and any protein combined with a druga polynucleotideanother proteina chemical entityanother functional entityused as medical binders or fillers; pharmaceutical preparationsnamely bioconjugatesintended for the diagnosis and treatment of diseasescancer ; antibody productsantibody or protein bioconjugates for the medical diagnosis and treatment of cancerantibody/protein drug conjugatesantibody/protein labeled conjugates and antibody/protein imaging agent conjugates; delivery devices for antibodiesdrugs delivery agent in the form of antibodies drug conjugates that facilitate the delivery and action of medical preparations ; molecules and biomoleculesreagentsantibody fragmentsantibodiesall intended for medical diagnosis and disease treatment; pharmaceutical productspreparations and medical articlesantibodiesantibody conjugates and active principles and antibody conjugates for medical purposes; chemical reagents for medical usechemical reagents to bind molecules for medical use; chemical reagents for the functionalization of biomolecules for medical use
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/03/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/03/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/03/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
14/03/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
14/03/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/04/2022
FIMP
FINAL DISPOSITION PROCESSED
18/04/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
26/10/2021
GPNX
NOTIFICATION PROCESSED BY IB
15/08/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/08/2021
PUBO
PUBLISHED FOR OPPOSITION
10/08/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/07/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
28/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/06/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/06/2021
RFNT
REFUSAL PROCESSED BY IB
24/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/01/2021
RFRR
REFUSAL PROCESSED BY MPU
05/01/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/12/2020
CNRT
NON-FINAL ACTION WRITTEN
18/12/2020
MAFR
APPLICATION FILING RECEIPT MAILED
18/12/2020
DOCK
ASSIGNED TO EXAMINER
14/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/12/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/12/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PSARLINK ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.